文献速递肿瘤 PET/CT核素与放射性配体治疗

半剂量[68Ga]Ga-PSMA-11全身PET/CT对生化复发前列腺癌的诊断价值与全剂量短轴视野PET/CT相当

Total-body PET/CT with half-dose [68 Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [68 Ga]Ga-PSMA-11.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-11

本研究回顾性纳入52例根治性前列腺切除术后生化复发(BCR)患者,行半剂量(0.9-1.1 MBq/kg)[68Ga]Ga-PSMA全身PET/CT,并与52例基线匹配、行全剂量(1.8-2.2 MBq/kg)常规短轴视野PET/CT的BCR患者比较。半剂量组再分5分钟(G5)与2分钟(G2)采集亚组。结果显示G2与全剂量组主观图像质量无显著差异(p>0.05),G5图像质量显著高于G2和全剂量组(均p<0.001),G2与全剂量组TBR无差异(4.23±5.21 vs 4.22±3.97,p=0.99)。结论认为半剂量全身PET/CT图像质量优于或相当于常规PET/CT,可满足BCR诊断需求并减少辐射暴露。

要点

  • 半剂量全身PET/CT的2分钟采集与全剂量常规PET/CT主观图像质量无显著差异(p>0.05)。
  • 5分钟采集图像质量显著高于2分钟采集和全剂量组(均p<0.001)。
  • 2分钟采集与全剂量组肿瘤-本底比无差异(4.23±5.21 vs 4.22±3.97,p=0.99)。

核心结论

  • 半剂量[68Ga]Ga-PSMA全身PET/CT图像质量优于或相当于常规PET/CT,可满足BCR患者诊断需求,尤其适用于对长时间水平体位和扫描时长耐受性降低者,同时减少受试者辐射暴露。

研究设计与样本

  • 回顾性研究,纳入52例根治性前列腺切除术后生化复发前列腺癌患者行半剂量(0.9-1.1 MBq/kg)[68Ga]Ga-PSMA全身PET/CT,并按基线特征匹配52例同行全剂量(1.8-2.2 MBq/kg)常规PET/CT的BCR患者。
  • 半剂量组进一步分为5分钟采集亚组(G5)和2分钟采集亚组(G2)。

主要发现

  • G2与全剂量组主观图像质量无显著差异(p>0.05)。
  • G5图像质量显著高于G2(p<0.001)和全剂量组(p<0.001)。
  • G2与全剂量组肿瘤-本底比无差异(4.23±5.21 vs 4.22±3.97,p=0.99)。
  • G2肝脏本底变异显著低于全剂量组(0.16±0.03 vs 0.20±0.05,p<0.001)。

关键数值与推荐

  • 半剂量为0.9-1.1 MBq/kg,全剂量为1.8-2.2 MBq/kg。
  • 图像质量采用5分法主观分析,并客观测量SUVmax、SUVmean及肝脏、血池、腮腺的本底变异(BV)。
  • 病灶计算SUVmax和肿瘤-本底比(TBR)。

临床怎么用

  • 作者认为半剂量[68Ga]Ga-PSMA全身PET/CT可满足BCR患者的诊断需求,尤其适用于对长时间水平体位和扫描时长耐受性降低者,同时减少受试者辐射暴露。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to evaluate the diagnostic performance and image quality of total-body positron emission tomography/computed tomography (PET/CT) imaging using a half-dose of [68 Ga]Ga-prostate specific membrane antigen ([68 Ga]Ga-PSMA) radiotracer, compared to conventional short axial field-of-view PET/CT imaging using a full dose of [68 Ga]Ga-PSMA. METHODS: This retrospective study enrolled 52 patients with biochemical recurrent (BCR) prostate cancer after radical prostatectomy who underwent total-body PET/CT with a half-dose (0.9-1.1 MBq/kg) of [68 Ga]Ga-PSMA. These patients were matched by baseline characteristics to another 52 BCR patients after prostatectomy who underwent conventional PET/CT with a full dose (1.8-2.2 MBq/kg) of [68 Ga]Ga-PSMA. The half-dose group was further divided into 5-min (G5) and 2-min (G2) acquisition subgroups. Image quality was assessed through subjective analysis using a 5-point scale and objective measurements of standard uptake value maximum (SUVmax), standard uptake value mean (SUVmean), background variation (BV) of the liver, blood pool, and parotid glands. Additionally, SUVmax and tumor-to-background ratio (TBR) were calculated for lesions. RESULTS: No significant difference in subjective image quality was found between the G2 and full-dose groups (p > 0.05). PET/CT image quality was significantly higher for the G5 versus G2 (p < 0.001) and full-dose groups (p < 0.001). TBR did not differ between the G2 and full-dose groups (4.23 ± 5.21 vs 4.22 ± 3.97, p = 0.99). Liver BV was significantly lower for G2 versus full-dose groups (0.16 ± 0.03 vs 0.20 ± 0.05, p < 0.001). CONCLUSIONS: Total-body PET/CT with a half-dose [68 Ga]Ga-PSMA yields image quality superior or comparable to that of conventional PET/CT. The utilization of total-body [68 Ga]Ga-PSMA PET/CT meets the diagnostic demands of BCR patients, particularly those who exhibit reduced tolerance to prolonged horizontal positioning and scan durations, while simultaneously reducing radiation exposure for the subjects.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu Y, Li L, Qin Y, et al. Total-body PET/CT with half-dose [68 Ga]Ga-PSMA-11 for biochemical recurrent prostate cancer: comparable diagnostic value to short axial field-of-view PET/CT with full-dose [68 Ga]Ga-PSMA-11. Eur J Nucl Med Mol Imaging. 2023. PMID: 37819451. doi:10.1007/s00259-023-06466-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。